Vitamin D and cancer

Frontiers in Endocrinology

Volumn 3, Issue APR, 2012, Pages

  Vuolo, Laura ^a   Di Somma, Carolina ^b   Faggiano, Antongiulio ^a   Colao, Annamaria ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b IRCCS SDN   (Italy)

Author keywords

25 hydroxy vitamin D; Cancer; Immunity; Inflammation; Vitamin D

Indexed keywords

EID: 84870796446     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2012.00058     Document Type: Review

References (126)

1. Abbas, S., Linseisen, J., Slanger, T., Kropp, S., Mutschelknauss, E. J., Flesch-Janys, D., and Chang-Claude, J. (2008). Serum 25-hydroxyvitamin D and risk of post-menopausal breast cancer results of a large case-control study. Carcinogenesis 29, 93-99.
2. Ahn, J., Albanes, D., Berndt, S. I., Peters, U., Chatterjee, N., Freedman, N. D., Abnet, C. C., Huang, W. Y., Kibel, A. S., Crawford, E. D., Weinstein, S. J., Chanock, S. J., Schatzkin, A., Hayes, R. B., and Prostate, Lung, Colorec-tal and Ovarian Trial Project Team. (2009). Vitamin D-related genes, serum vitamin D concentrations and prostate cancer risk. Carcinogenesis 30, 769-776.
3. Ali, M. M., and Vaidya, V. (2007). Vit-amin D and cancer. J. Cancer Res. Ther. 3, 225-230.
4. Apperly, F. L. (1941). The relation of solar radiation to cancer mortality in North American. Cancer Res. 1, 191-195.
5. Baier, R., Grauer, A., Lazaretti-Castro, M., Ziegler, R., and Raue, F. (1994). Differential effects of 25-hydroxyvitamin D on cell prolifera-tion and calcitonin gene expression. Endocrinology 135, 2006-2011.
6. Bao, B. Y., Yao, J., and Lee, Y. F. (2006). 1{alpha}, 25-dihydroxyvitamin D3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis. Carcinogenesis 27, 1883-1893.
7. Barnett, C. M., Nielson, C. M., Shan-non, J., Chan, J. M., Shikany, J. M., Bauer, D. C., Hoffman, A. R., Barrett-Connor, E., Orwoll, E., and Beer, T. M. (2010). Serum 25-OH vitamin D levels and risk of developing prostate cancer in older men. Cancer Causes Control 21, 1297-1303.
8. Beer, T. M., Munar, M., and Henner, W. D. (2001). A phase I trial of pulse calcitriol in patients with refractory malignancies: pulse dosing permits substantial dose escalation. Cancer 91, 2431-2439.
9. Beer,T. M.,and Myrthue,A. (2004). Cal-citriol in cancer treatment: from the lab to the clinic. Mol. Cancer Ther. 3, 373-338.
10. Beildeck, M. R., and Byers, S. W. (2009). Vitamin D analogues in colon cancer prevention and care. Curr. Colorectal Cancer Rep. 5, 185-196.
11. Bernardi, R. J., Johnson, C. S., Modzelewski, R. A., and Trump, D. L. (2002). Antiproliferative effects of 1alpha,25-dihydroxyvitamin D(3) and vitamin D analogs on tumor-derived endothelial cells. Endocrinology 143, 2508-2514.
12. Bhalla, A. K., Amento, E. P., Clemens, T. L., Holick, M. F., and Krane, S. M. (1983). Specific high-affinity receptors for 1,25-dihydroxyvitamin D3 in human peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation. J. Clin. Endocrinol. Metab. 57, 1308-1310.
13. Bischoff-Ferrari, H. A., Giovannucci, E., Willett, W. C., Dietrich, T., and Dawson-Huges, B. (2006). Estima-tion of optimal serum concentra-tions of 25-hydroxyvitamin D for multiple health outcomes. Am. J. Clin. Nutr. 84, 18-28.
14. Boscoe, F. P., and Schymura, M. J. (2006). Solar ultraviolet-B exposure and cancer incidence and mortality in the United States. BMC Cancer 10, 264-314. doi:10.1186/1471-2407-6-264.
15. Byers, S. W., Rowlands, T., Beildeck, M., and Bong, Y. S. (2012). Mechanism of action of vitamin D and the vit-amin D receptor in colorectal can-cer prevention and treatment. Rev. Endocr. Metab. Disord. 13, 31-38.
16. Chadha, M. K., Tian, L., Mashtare, T., Payne, V., Silliman, C., Levine, E., Wong, M., Johnson, C., and Trump, D. L. (2010). Phase 2 trial of weekly intravenous 1,25 dihydroxy chole-calciferol (calcitriol) in combination with dexamethasone for castration-resistant prostate cancer. Cancer 116, 2132-2139.
17. Chen, L., Davey Smith, G., Evans, D. M., Cox, A., Lawlor, D. A., Dono-van, J., Yuan, W., Day, I. N., Mar-tin, R. M., Lane, A., Rodriguez, S., Davis, M., Zuccolo, L., Collin, S. M., Hamdy, F., Neal, D., and Lewis, S. J. (2009). Genetic variants in the vita-min d receptor are associated with advanced prostate cancer at diag-nosis: findings from the prostate testing for cancer and treatment study and a systematic review. Can-cer Epidemiol. Biomarkers Prev. 18, 2874-2881.
18. Chen, T. C., and Kittaka, A. (2011). Novel vitamin d analogs for prostate cancer therapy. ISRN Urol. 2011, 301490.
19. Chung,I.,Han,G.,Seshadri,M.,Gillard, B. M., Yu, W. D., Foster, B. A., Trump, D. L., and Johnson, C. S. (2009). Role of vitamin D receptor in the antiproliferative effects of cal-citriol in tumor-derived endothelial cells and tumor angiogenesis in vivo. Cancer Res. 69, 967-975.
20. Clinckspoor, I., Verlinden, L., Over-bergh, L., Korch, C., Bouillon, R., Mathieu, C., Verstuyf, A., and Decallonne, B. (2011). 1,25-Dihydroxyvitamin D3 and a superagonistic analog in combination with paclitaxel or suberoylanilide hydroxamic acid have potent antiproliferative effects on anaplastic thyroid cancer. J. Steroid Biochem. Mol. Biol. 124, 1-9.
21. Colston, K. W. (2008). Vitamin D and breast cancer risk. Best Pract. Res. Clin. Endocrinol. Metab. 22, 587-599.
22. Coussens, L. M., and Werb, Z. (2002). Inflammation and cancer. Nature 420, 860-867.
23. Cross, H. S. (2007). Extrarenal vita-min D hydroxylase expression and activity in normal and malignant cells: modification of expression by epigenetic mechanisms and dietary substances. Nutr. Rev. 65(8 Pt 2), S108-S112.
24. De Haes, P., Garmyn, M., Ver-stuyf, A., De Clercq, P., Vande-walle, M., Vantieghem, K., Degreef, H., Bouillon, R., and Segaert, S. (2004). Two 14-epi analogues of 1, 25-dihydroxyvitamin D3 protect human keratinocytes against the effects of UVB. Arch. Dermatol. Res. 295, 527-534.
25. Deeb, K. K., Trump, D. L., and John-son, C. S. (2007). Vitamin D sig-nalling pathways in cancer: potential for anticancer therapeutics. Nat. Rev. Cancer 7, 684-700.
26. Ding, E. L., Mehta, S., Fawzi, W. W., and Giovannucci, E. L. (2008). Interac-tion of estrogen therapy with cal-cium and vitamin D supplemen-tation on colorectal cancer risk: reanalysis of Women's Health Initia-tive randomized trial. Int. J. Cancer 122, 1690-1694.
27. Dreijerink, K. M., Varier, R. A., van Nuland, R., Broekhuizen, R., Valk, G. D., van der Wal, J. E., Lips, C. J., Kummer, J. A., and Timmers, H. T. (2009). Regulation of vitamin D receptor function in MEN1-related parathyroid adenomas. Mol. Cell. Endocrinol. 313, 1-8.
28. Egan, K. M. (2009). Vitamin D and melanoma. Ann. Epidemiol. 19, 455-461.
29. Evans, R. M. (1988). The steroid and thyroid hormone receptor super-family. Science 240, 889-895.
30. Evans, S. R., Houghton, A. M., Schu-maker, L., Brenner, R. V., Buras, R. R., Davoodi, F., Nauta, R. J., and Shabahang, M. (1996). Vitamin D receptor and growth inhi-bition by 1,25-dihydroxyvitamin D3 in human malignant melanoma cell lines. J. Surg. Res. 61, 127-133.
31. Feskanich, D., Ma, J., Fuchs, C. S., Kirkner, G. J., Hankinson, S. E., Hol-lis, B. W., and Giovannucci, E. L. (2004). Plasma vitamin D metabo-lites and risk of colorectal cancer in women. Cancer Epidemiol. Biomark-ers Prev. 13, 1502-1508.
32. Fleet, J. C. (2008). Molecular actions of vitamin D contributing to can-cer prevention. Mol. Aspects Med. 29, 388-396.
33. Friedrich, M., Diesing, D., Cordes, T., Fischer, D., Becker, S., Chen, T. C., Flanagan, J. N., Tangpricha, V., Gherson, I., Holick, M. F., and Reichrath, J. (2006). Analysis of 25-hydroxyvitamin D3-1alpha-hydroxylase in normal and malig-nant breast tissue. Anticancer Res. 26, 2615-2620.
34. Galbiati, F., Polastri, L., Gregori, S., Freschi, M., Casorati, M., Cavallaro, U., Fiorina, P., Bertuzzi, F., Zerbi, A., Pozza, G., Adorini, L., Folli, F., Christofori, G., and Davalli, A. M. (2002). Antitumorigenic and anti-insulinogenic effects of calcitriol on insulinoma cells and solid beta-cell tumors. Endocrinology 143, 4018-4030.
35. Gandini, S., Raimondi, S., Gnagnarella, P., Doré, J. F., Maisonneuve, P., and Testori, A. (2009). Vitamin D and skin cancer: a meta-analysis. Eur. J. Cancer 45, 634-641.
36. Garland,C. F.,and Garland,F. C. (1980). Do sunlight and vitamin D reduce the likelihood of colon cancer? Int. J. Epidemiol. 9, 227-231.
37. Garland, C. F., Gorham, E. D., Mohr, S. B., Grant, W. B., Giovannucci, E. L., Lipkin,M.,Newmark,H.,Holick,M. F., and Garland, F. C. (2007). Vit-amin D and prevention of breast cancer: pooled analysis. J. Steroid Biochem. Mol. Biol. 103, 708-711.
38. Getzenberg, R. H., Light, B. W., Lapco, P. E., Konety, B. R., Nangia, A. K., Acierno, J. S., Dhir, R., Shurin, Z., Day, R. S., Trump, D. L., and Johnson, C. S. (1997). Vitamin D inhibition of prostate adenocarci-noma growth and metastasis in the Dunning rat prostate model system. Urology 50, 999-1006.
39. Gilbert, R., Martin, R. M., Beynon, R., Harris, R., Savovic, J., Zuccolo, L., Bekkering, G. E., Fraser, W. D., Sterne, J. A., and Metcalfe, C. (2011). Associations of circulating and dietary vitamin D with prostate cancer risk: a systematic review and doseresponse meta-analysis. Cancer Causes Control 22, 319-340.
40. Giovannucci, E., Liu, Y., Rimm, E. B., Hollis, B. W., Fuchs, C. S., Stampfer, M. J., and Willett, W. C. (2006). Prospective study of predictors of vitamin D status and cancer inci-dence and mortality in men. J. Natl. Cancer Inst. 98, 451-459.
41. Gorham, E. D., Garland, C. F., Garland, F. C., Grant, W. B., Mohr, S. B., Lip-kin, M., Newmark, H. L., Giovan-nucci, E., Wei, M., and Holick, M. F. (2007). Optimal vitamin D sta-tus for colorectal cancer prevention: a quantitative meta analysis. Am. J. Prev. Med. 32, 210-216.
42. Grant, W. B., and Garland, C. F. (2006). The association of solar ultraviolet B (UVB) with reducing risk of can-cer: multifactorial ecologic analysis of geografic variation in age adjusted cancer mortality rates. Anticancer Res. 26, 2687-2699.
43. Grant, W. B., Juzeniene, A., and Moan, J. E. (2011). Review Article: health benefit of increased serum 25(OH)D levels from oral intake and ultraviolet-B irradiance in the Nordic countries. Scand. J. Public Health 39, 70-78.
44. Gross, C., Stamey, T., Hancock, S., and Feldman, D. (1998). Treatment of early recurrent prostate can-cer with 1,25-dihydroxyvitamin D3 (calcitriol). J. Urol. 159, 2035-2039.
45. Gupta, D., Lammersfeld, C. A., Trukova, K., and Lis, C. G. (2009). Vitamin D and prostate cancer risk: a review of the epidemiological liter-ature. Prostate Cancer Prostatic Dis. 12, 215-226.
46. Haussler, M. R., Whitfield, G. K., Haus-sler, C. A., Hsieh, J. C., Thompson, P. D., Selznick, S. H., Dominguez, C. E., and Jurutka, P. W. (1998). The nuclear vitamin D receptor: biolog-ical and molecular regulatory prop-erties revealed. J. Bone Miner. Res. 13, 325-349.
47. Haverkamp, J., Charbonneau, B., and Ratliff, T. L. (2008). Prostate inflam-mation and its potential impact on prostate cancer: a current review. J. Cell. Biochem. 103, 1344-1353.
48. Holick, M. F., and Chen, T. C. (2008). Vitamin d deficiency: a worldwide problem with health consequences. Am. J. Clin. Nutr. 87, 1080S-1086S.
49. Hsieh, J. C., Jurutka, P. W., Galligan, M. A., Terpening, C. M., Haussler, C. A., Samuels, D. S., Shimizu, Y., Shimizu, N., and Haussler, M. R. (1991). Human vitamin D receptor is selectively phosphorylated by pro-tein kinase C on serine 51, a residue crucial to its trans-activation func-tion. Proc. Natl. Acad. Sci. U.S.A. 88, 9315-9319.
50. Hutchinson, M. S., Grimnes, G., Joakimsen, R. M., Figenschau, Y., and Jorde, R. (2010). Low serum 25 hydroxyvitamin D levels are associ-ated with increased all-cause mortal-ity risk in a general population: the Tromsø study. Eur. J. Endocrinol. 162, 935-942.
51. Jacobs, E. T., Giuliano, A. R., Martinez, M. E., Hollis, B. W., Reid, M. E., and Marshall, J. R. (2004). Plasma levels of 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and the risk of prostate cancer. J. Steroid Biochem. Mol. Biol. 89-90, 533-537.
52. Jacobs, E. T., Thomson, C. A., Flatt, S. W., Al-Delaimy, W. K., Hibler, E. A., Jones, L. A., Leroy, E. C., New-man, V. A., Parker, B. A., Rock, C. L., and Pierce, J. P. (2011). Vitamin D and breast cancer recurrence in the Women's Healthy Eating and Living (WHEL) Study. Am. J. Clin. Nutr. 93, 108-117.
53. Janowsky, E. C., Lester, G. E., Weinberg, C. R., Millikan, R. C., Schildkraut, J. M., Garrett, P. A., and Hulka, B. S. (1999). Association between low levels of 1,25 dihydroxyvitamin D and breast cancer risk. Public Health Nutr. 2, 283-291.
54. Jenab, M., Bueno-de-Mesquita, H. B., Ferrari, P., van Duijnhoven, F. J., Norat, T., Pischon, T., Jansen, E. H., Slimani, N., Byrnes, G., Rinaldi, S., Tjønneland, A., Olsen, A., Overvad, K., Boutron-Ruault, M. C., Clavel-Chapelon, F., Morois, S., Kaaks, R., Linseisen, J., Boeing, H., Bergmann, M. M., Trichopoulou, A., Misirli, G., Trichopoulos, D., Berrino, F., Vineis, P., Panico, S., Palli, D., Tumino, R., Ros, M. M., van Gils, C. H., Peeters, P. H., Brustad, M., Lund, E., Tormo,M. J., Ardanaz,E., Rodríguez, L., Sánchez, M. J., Dorronsoro, M., Gonzalez, C. A., Hallmans, G., Palmqvist, R., Roddam, A., Key, T. J., Khaw, K. T., Autier, P., Hainaut, P., and Riboli, E. (2010). Association between pre-diagnostic circulating vitamin D concentration and risk of colorectal cancer in European pop-ulations:a nested case-control study. BMJ 340, b5500.
55. Kemmochi, S., Fujimoto, H., Woo, G. H., Hirose, M., Nishikawa, A., Mitsumori, K., and Shibutani, M. (2011). Preventive effects of cal-citriol on the development of capsu-lar invasive carcinomas in a rat two-stage thyroid carcinogenesis model. J. Vet. Med. Sci. 73, 655-664.
56. Khadzkou, K., Buchwald, P., Westin, G., Dralle, H., Akerström, G., and Hellman, P. (2006). 25 hydroxyvi-tamin D3 1alpha-hydroxylase and vitamin D receptor expression in papillary thyroid carcinoma. J. His-tochem. Cytochem. 54, 355-361.
57. Kostner, K., Denzer, N., Muller, C. S., Klein, R., Tilgen, W., and Reichrath, J. (2009). The relevance of vitamin D receptor (VDR) gene polymorphism for cancer: a review of the literature. Anticancer Res. 29, 3511-3536.
58. Krishnan, A. V., Moreno, J., Nonn, L., Swami, S., Peehl, D. M., and Feldman, D. (2007). Calcitriol as a chemopreventive and therapeutic agent in prostate cancer: role of anti-inflammatory activity. J. Bone Miner. Res. 22(Suppl. 2), V74-V80.
59. Lee, J. H., Park, S., Cheon, S., Lee, J. H., Kim, S., Hur, D. Y., Kim, T. S., Yoon, S. R., Yang, Y., Bang, S. I., Park, H., Lee, H. T., and Cho, D. (2011). 1,25-Dihydroxyvitamin D(3) enhances NK susceptibility of human melanoma cells via Hsp60-mediated FAS expression. Eur. J. Immunol. 41, 2937-2946.
60. Lee, J. H., and Youn, J. I. (1998). The photoprotective effect of 1, 25-Dihydroxyvitamin D3 on ultraviolet B-induced damage in keratinocyte and its mechanisms of action. J. Dermatol. Sci. 18, 11-18.
61. Lin, R., Nagai, Y., Sladek, R., Bastien, Y., Ho, J., Petrecca, K., Sotiropoulou, G., Diamandis, E. P., Hudson, T. J., and White, J. H. (2002). Expression pro-filing in squamous carcinoma cells reveals pleiotropic effects of vita-min D3 analog EB1089 signaling on cell proliferation, differentiation, and immune system regulation. Mol. Endocrinol. 16, 1243-1256.
62. Liu, W., Asa, S. L., Fantus, I. G., Wal-fish, P. G., and Ezzat, S. (2002). Vitamin D arrests thyroid carci-noma cell growth and induces p27 dephosphorylation and accumula-tion through PTEN/akt-dependent and independent pathways. Am. J. Pathol. 160, 511-519.
63. Lou, Y. R., Laaksi, I., Syvälä, H., Bläuer, M., Tammela, T. L., Ylikomi, T., and Tuohimaa, P. (2004). 25-Hydroxyvitamin D3 is an active hor-mone in human primary prostatic stromal cells. FASEB J. 18, 332-334.
64. Lowe, L. C., Guy, M., Mansi, J. L., Peckitt, C., Bliss, J., Wilson, R. G., and Colston, K. W. (2005). Plasma 25-hydroxy vitamin D concentra-tions, vitamin D receptor genotype and breast cancer risk in a UK Cau-casian population. Eur. J. Cancer 41, 1164-1169.
65. Lucia, M. S., and Torkko, K. C. (2004). Inflammation as a target for prostate cancer chemoprevention: patholog-ical and laboratory rationale. J. Urol. 171, S30-S34.
66. Ma, J., Stampfer, M. J., Gann, P. H., Hough, H. L., Giovannucci, E., Kelsey, K. T., Hennekens, C. H., and Hunter, D. J. (1998). Vitamin D receptor polymorphisms, circu-lating vitamin D metabolites, and risk of prostate cancer in United States physicians. Cancer Epidemiol. Biomarkers Prev. 7, 385-390.
67. Manolagas, S. C., Werntz, D. A., Tsoukas, C. D., Provvedini, D. M., and Vaughan, J. H. (1986). 1,25-Dihydroxyvitamin D3 receptors in lymphocytes from patients with rheumatoid arthritis. J. Lab. Clin. Med. 108, 596-600.
68. Mantell, D. J., Owens, P. E., Bun-dred, N. J., Mawer, E. B., and Canfield, A. E. (2000). 1 alpha,25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ. Res. 87, 214-220.
69. Martineau,A. R.,Wilkinson,K.A.,New-ton, S. M., Floto, R. A., Norman, A. W., Skolimowska, K., Davidson, R. N., Sørensen, O. E., Kampmann, B., Griffiths, C. J., and Wilkinson, R. J. (2007). IFN-gamma-and TNF-independent vitamin D-inducible human suppression of mycobacte-ria: the role of cathelicidin LL-37. J. Immunol. 178, 7190-7198.
70. Matusiak, D., Murillo, G., Carroll, R. E., Mehta, R. G., and Benya, R. V. (2005). Expression of vitamin D receptor and 25-hydroxyvitamin D3-1{alpha}-hydroxylase in normal and malignant human colon. Can-cer Epidemiol. Biomarkers Prev. 14, 2370-2376.
71. McCullough, M. L., Bostick, R. M., and Mayo, T. L. (2009). Vitamin D gene pathway polymorphisms and risk of colorectal, breast, and prostate cancer. Annu.Rev.Nutr.29,111-132.
72. McGuire, T. F., Trump, D. L., and Johnson, C. S. (2001). Vitamin D3-induced apoptosis of murine squa-mous cell carcinoma cells: selec-tive induction of caspase-dependent MEK cleavage and up-regulation of MEKK-1. J. Biol. Chem. 276, 26365-26373.
73. Merke, J., Milde, P., Lewicka, S., Hügel, U., Klaus, G., Mangelsdorf, D. J., Haussler, M. R., Rauter-berg, E. W., and Ritz, E. (1989). Identification and regulation of 1,25-dihydroxyvitamin D3 receptor activity and biosynthesis of 1,25-dihydroxyvitamin D3. Studies in cultured bovine aortic endothelial cells and human dermal capillaries. J. Clin. Invest. 83, 1903-1915.
74. Mohr, S. B., Garland, C. F., Gorham, E. D., Grant, W. B., and Garland, F. C. (2008). Relationship between low ultraviolet B irradiance and higher breast cancer risk in 107 countries. Breast J. 14, 255-260.
75. Morelli, S., Buitrago, C., Boland, R., and de Boland,A. R. (2001). The stimula-tion of MAP kinase by 1,25(OH)(2)-vitamin D(3) in skeletal muscle cells is mediated by protein kinase C and calcium. Mol. Cell. Endocrinol. 173, 41-52.
76. Morris, M. J., Smaletz, O., Solit, D., Kelly, W. K., Slovin, S., Flombaum, C.,Curley,T.,Delacruz,A.,Schwartz, L., Fleisher, M., Zhu, A., Diani, M., Fallon, M., and Scher, H. I. (2004). High-dose calcitriol, zole-dronate, and dexamethasone for the treatment of progressive prostate carcinoma. Cancer 100, 1868-1875.
77. Muindi, J. R., Peng, Y., Potter, D. M, Hershberger, P. A., Tauch, J. S., Capozzoli, M. J., Egorin, M. J., Johnson, C. S., and Trump, D. L. (2002). Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and pacli-taxel. Clin. Pharmacol. Ther. 72, 648-659.
78. Nakagawa, K., Kawaura, A., Kato, S., Takeda, E., and Okano, T. (2005). 1 alpha,25-Dihydroxyvitamin D(3) is a preventive factor in the metasta-sis of lung cancer. Carcinogenesis 26, 429-440.
79. Narayanan, B. A., Narayanan, N. K., Davis, L., and Nargi, D. (2006). RNA interference-mediated cyclooxygenase-2 inhibition pre-vents prostate cancer cell growth and induces differentiation: modulation of neuronal protein synaptophysin, cyclin D1, and androgen receptor. Mol. Cancer Ther. 5, 1117-1125.
80. Nemere, I., Farach-Carson, M. C., Rohe, B., Sterling, T. M., Norman, A. W., Boyan, B. D., and Safford, S. E. (2004). Ribozyme knockdown func-tionally links a 1,25(OH)2D3 mem-brane binding protein (1,25D3-MARRS) and phosphate uptake in intestinal cells. Proc. Natl. Acad. Sci. U.S.A. 101, 7392-7397.
81. Newton-Bishop, J. A., Beswick, S., Randerson-Moor, J., Chang, Y. M., Affleck, P., Elliott, F., Chan, M., Leake, S., Karpavicius, B., Haynes, S., Kukalizch, K., Whitaker, L., Jack-son, S., Gerry, E., Nolan, C., Bertram, C., Marsden, J., Elder, D. E., Bar-rett, J. H., and Bishop, D. T. (2009). Serum 25-hydroxyvitamin D3 levels are associated with breslow thick-ness at presentation and survival from melanoma. J. Clin. Oncol. 27, 5439-5444.
82. Norman, A. W. (1998). Sunlight, sea-son, skin pigmentation, vitamin D and 25-hydroxyvitamin D: inte-gral components of the vitamin D endocrine system. Am. J. Clin. Nutr. 67, 1108-1110.
83. Norman, A. W. (2006). Vitamin D receptor: new assignments for an already busy receptor. Endocrinology 147, 5542-5548.
84. Nürnberg, B., Gräber, S., Gärtner, B., Geisel, J., Pföhler, C., Schaden-dorf, D., Tilgen, W., and Reichrath, J. (2009). Reduced serum 25-hydroxyvitamin D levels in stage IV melanoma patients. Anticancer Res. 29, 3669-3674.
85. Osborn, J. L., Schwartz, G. G., Smith, D. C., Bahnson, R., Day, R., and Trump, D. L. (1995). Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refrac-tory prostate cancer. Urol. Oncol. 1, 195-198.
86. Peehl, D. M., Skowronski, R. J., Leung, G. K., Wong, S. T., Stamey, T. A., and Feldman, D. (1994). Antiprolifera-tive effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res. 54, 805-810.
87. Pelczynska, M., Wietrzyk, J., Jaroszewicz, I., Nevozhay, D., Switalska, M., Kutner, A., Zabel, M., and Opolski, A. (2005). Correla-tion between VDR expression and antiproliferative activity of vitamin D3 compounds in combination with cytostatics. Anticancer Res. 25, 2235-2240.
88. Pendás-Franco, N., García, J. M., Peña, C., Valle, N., Pálmer, H. G., Heinäniemi, M., Carlberg, C., Jiménez, B., Bonilla, F., Muñoz, A., and González-Sancho, J. M. (2008). DICKKOPF-4 is induced by TCF/beta-catenin and upregulated in human colon cancer, promotes tumour cell invasion and angiogen-esis and is repressed by 1alpha,25-dihydroxyvitamin D3. Oncogene 27, 4467-4477.
89. Penna-Martinez, M., Ramos-Lopez, E., Stern, J., Hinsc, N., Hansmann, M. L., Selkinski, I., Grünwald, F., Vor-länder, C., Wahl, R. A., Bechstein, W. O., Zeuzem, S., Holzer, K., and Badenhoop, K. (2009). Vitamin D receptor polymorphisms in differ-entiated thyroid carcinoma. Thyroid 19, 623-628.
90. Peterlik, M., Grant, W. B., and Cross, H. S. (2009). Calcium, vitamin D and cancer. Anticancer Res. 29, 3687-3698.
91. Petrioli, R., Pascuccu, A., Francinin, E., Marsili, S., Sciandiviasci, A., De Rubertis, G., Barbanti, G., Manganelli, A., Salvestrini, F., and Francini, G. (2007). Weekly high-dose calcitriol and docetaxel in patients with metastatic hormone-refractory prostate cancer previously exposed to docetaxel. BJU Int. 100, 775-779.
92. Pilz, S., Dobnig, H., Winklhofer-Roob, B., Riedmuller, G., Fischer, J. E., and Seelhorst, U. (2008). Low serum levels of 25-hydroxyvitamin D predict fatal cancer in patients referred to coronary angiography. Cancer Epidemiol. Biomarkers Prev. 17, 1228-1233.
93. Pochet, R., Blachier, F., Lawson, D. E., and Malaisse, W. J. (1989). Presence of calbindin-D 28K in endocrine pancreatic tumoral cells of the RINm5F line. Int. J. Pancreatol. 5, 295-304.
94. Raimondi, S., Johansson, H., Maison-neuve, P., and Gandini, S. (2009). Review and meta-analysis on vit-amin D receptor polymorphism and cancer risk. Carcinogenesis 30, 1170-1180.
95. Reichekl, H., Koeffler, H. P., and Nor-man, A. W. (1989). The role of vita-min D endocrine system in health and disease. N.Engl.J.Med.320, 980-991.
96. Reichrath, J., Friedrich, M., and Vogt, T. (2012). Vitamin D and its analogs in cancer prevention and therapy. Anticancer Res. 32, 209-210.
97. Robsahm, T. E., Tretli, S., Dahlback, A., and Moan, J. (2004). Vitamin D3 from sunlight may improve the prognosis of breast, colon and prostate cancer (Norway). Cancer Causes Control 15, 149-158.
98. Schwartz, G. G. (2009). Vitamin D and intervention trials in prostate can-cer: from theory to therapy. Ann Epidemiol 19, 96-102.
99. Schwartz, G. G., Eads, D., Rao, A., Cramer, S. D., Willingham, M. C., Chen, T. C., Jamieson, D. P., Wang, L., Burnstein, K. L., Holick, M. F., and Koume-nis, C. (2004). Pancreatic cancer cells express 25-hydroxyvitamin D-1 alpha-hydroxylase and their prolif-eration is inhibited by the prohor-mone 25-hydroxyvitamin D3. Car-cinogenesis 25, 1015-1026.
100. Schwartz, G. G., and Hulka, B. S. (1990). Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res. 10, 1307-1311.
101. Seifert, M., Rech, M., Meineke, V., Tilgen, W., and Reichrath, J. (2004). Differential biological effects of 1,25-dihydroxyVitamin D3 on melanoma cell lines in vitro. J. Steroid Biochem. Mol. Biol. 89-90, 375-379.
102. Seoane, S., Ben, I., Centeno, V., and Perez-Fernandez, R. (2007). Cellu-lar expression levels of the vitamin D receptor are critical to its tran-scriptional regulation by the pitu-itary transcription factor Pit-1. Mol. Endocrinol. 21, 1513-1525.
103. Sertznig, P., Seifert, M., Tilgen, W., and Reichrath, J. (2009). Activation of vitamin D receptor (VDR)-and peroxisome proliferator-activated receptor (PPAR)-signaling path-ways through 1,25(OH)(2)D(3) in melanoma cell lines and other skin-derived cell lines. Dermatoendocrinol. 1, 232-238.
104. Seubwai, W., Wongkham, C., Puapairoj, A., Khuntikeo, N., and Wongkham, S. (2007). Overexpression of vitamin D receptor indicates a good progno-sis for cholangiocarcinoma: implica-tions for therapeutics. Cancer 109, 2497-2505.
105. Shah,S.,Islam,M. N.,Dakshanamurthy, S., Rizvi, I., Rao, M., Herrell, R., Zinser, G., Valrance, M., Aranda, A., Moras,D.,Norman,A.,Welsh,J.,and Byers, S. W. (2006). The molecular basis of vitamin D receptor and beta-catenin crossregulation. Mol. Cell 21, 799-809.
106. Sigmundsdottir, H., Pan, J., Debes, G. F., Alt, C., Habtezion, A., Soler, D., and Butcher, E. C. (2007). DCs metab-olize sunlight-induced vitamin D3 to "program" T cell attraction to the epidermal chemokine CCL27. Nat. Immunol. 8, 285-293.
107. Tang, J. Y., Fu, T., Leblanc, E., Man-son, J. E., Feldman, D., Linos, E., Vitolins, M. Z., Zeitouni, N. C., Lar-son, J., and Stefanick, M. L. (2011). Calcium plus vitamin D supplemen-tation and the risk of nonmelanoma and melanoma skin cancer: post hoc analyses of the women's health ini-tiative randomized controlled trial. J. Clin. Oncol. 29, 3078-3084.
108. Touvier, M., Chan, D. S., Lau, R., Aune, D., Vieira, R., Greenwood, D. C., Kampman, E., Riboli, E., Her-cberg, S., and Norat, T. (2011). Meta-analyses of vitamin D intake, 25-hydroxyvitamin D status, vit-amin D receptor polymorphisms, and colorectal cancer risk. Can-cer Epidemiol. Biomarkers Prev. 20, 1003-1016.
109. Townsend, K., Evans, K. N., Campbell, M. J., Colston, K. W., Adams, J. S., and Hewison, M. (2005). Biological actions of extra-renal 25-hydroxyvitamin D-1alpha-hydroxylase and implications for chemoprevention and treatment. J. Steroid Biochem. Mol. Biol. 97, 103-109.
110. Travis, R. C., Crowe, F. L., Allen, N. E., Appleby, P. N., Roddam,A. W., Tjøn-neland, A., Olsen, A., Linseisen, J., Kaaks, R., Boeing, H., Kröger, J., Tri-chopoulou, A., Dilis, V., Trichopou-los, D., Vineis, P., Palli, D., Tumino, R., Sieri, S., Bueno-de-Mesquita, H. B., van Duijnhoven, F. J., Chirlaque, M. D., Barricarte, A., Larrañaga, N., González, C. A., Argüelles, M. V., Sánchez, M. J., Stattin, P., Hallmans, G., Khaw, K. T., Bingham, S., Rinaldi, S., Slimani, N., Jenab, M., Riboli, E., and Key, T. J. (2009). Serum vitamin D and risk of prostate cancer in a case control analysis nested within the European Prospective Investigation into Cancer and Nutrition (EPIC). Am. J. Epidemiol. 169, 1223-1232.
111. Trémezaygues, L., Sticherling, M., Pföh-ler, C., Friedrich, M., Meineke, V., Seifert, M., Tilgen, W., and Reichrath,J. (2006). Cutaneous pho-tosynthesis of vitamin D: an evolu-tionary highly-conserved endocrine system that protects against envi-ronmental hazards including UV-radiation and microbial infections. Anticancer Res. 26, 2743-2748.
112. Trump, D. L., Deeb, K. K., and Johnson, C. S. (2010). Vitamin D: considera-tions in the continued development as an agent for cancer prevention and therapy. Cancer J. 16, 1-9.
113. Trump, D. L., Hershberger, P. A., Bernardi, R. J., Ahmed, S., Muindi, J., Fakih, M., Yu, W. D., and John-son, C. S. (2004). Anti-tumor activ-ity of calcitriol: pre-clinical and clin-ical studies. J. Steroid Biochem. Mol. Biol. 89-90, 519-526.
114. Trump, D. L., Potter, D. M., Muindi, J., Brufsky, A., and Johnson, C. S. (2006). Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexam-ethasone in androgen-independent prostate cancer. Cancer 106, 2136-2142.
115. Tuohimaa, P. (2008). Vitamin D, aging, and cancer. Nutr. Rev. 66(Suppl. 2), S147-S152.
116. Uhmann, A., Niemann, H., Lammer-ing, B., Henkel, C., Hess, I., Nitzki, F., Fritsch, A., Prüfer, N., Rosen-berger, A., Dullin, C., Schraepler, A., Reifenberger,J.,Schweyer,S.,Pietsch, T., Strutz, F., Schulz-Schaeffer, W., and Hahn, H. (2011). Antitumoral effects of calcitriol in basal cell carci-nomas involve inhibition of hedge-hog signaling and induction of vit-amin D receptor signaling and dif-ferentiation. Mol. Cancer Ther. 10, 2179-2188.
117. Veldman, C. M., Cantorna, M. T., and DeLuca, H. F. (2000). Expression of 1,25-dihydroxyvitamin D(3) recep-tor in the immune system. Arch. Biochem. Biophys. 374, 334-338.
118. Vrieling, A., Hein, R., Abbas, S., Schneeweiss, A., Flesch-Janys, D., and Chang-Claude, J. (2011). Serum 25-hydroxyvitamin D and post-menopausal breast cancer survival: a prospective patient cohort study. Breast Cancer Res. 13, R74.
119. Wactawski-Wende, J., Kotchen, J. M., Anderson, G. L., Assaf, A. R., Brun-ner, R. L., O'Sullivan, M. J., Margolis, K. L., Ockene, J. K., Phillips, L., Pot-tern, L., Prentice, R. L., Robbins, J., Rohan, T. E., Sarto, G. E., Sharma, S., Stefanick, M. L., Van Horn, L., Wallace, R. B., Whitlock, E., Bass-ford, T., Beresford, S. A., Black, H. R., Bonds, D. E., Brzyski, R. G., Caan, B., Chlebowski, R. T., Cochrane, B., Garland, C., Gass, M., Hays, J., Heiss, G., Hendrix, S. L., Howard, B. V., Hsia, J., Hubbell, F. A., Jackson, R. D., Johnson, K. C., Judd, H., Kooper-berg, C. L., Kuller, L. H., LaCroix, A. Z., Lane, D. S., Langer, R. D., Lasser, N. L., Lewis, C. E., Limacher, M. C., and Manson, J. E. (2006). Women's Health Initiative Investigators. Cal-cium plus vitamin D supplementa-tion and the risk of colorectal cancer. N.Engl.J.Med.354, 684-696.
120. Wali, R. K., Baum, C. L., Sitrin, M. D., and Brasitus, T. A. (1990). 1,25(OH)2 vitamin D3 stimu-lates membrane phosphoinositide turnover, activates protein kinase C, and increases cytosolic calcium in rat colonic epithelium. J. Clin. Invest. 85, 1296-1303.
121. Wang, Q. M., Jones, J. B., and Studzin-ski, G. P. (1996). Cyclin-dependent kinase inhibitor p27 as a medi-ator of the G1-S phase block induced by 1,25-dihydroxyvitamin D3 in HL60 cells. Cancer Res. 56, 264-267.
122. Woo, T. C. S., Choo, R., Jamieson, J., Chander, S., and Vieth, R. (2005). Pilot study: potential role of vitamin D (cholecalciferol) in patients with PSA replapse after definitive therapy. Nutr. Cancer 51, 32-36.
123. Yin, L., Grandi, N., Raum, E., Haug, U., Arndt, V., and Brenner, H. (2009). Meta-analysis: longitudinal studies of serum vitamin D and colorec-tal cancer risk. Aliment. Pharmacol. Ther. 30, 113-125.
124. Zabel, M., Flig, K., Gebarowska, E., and Surdyk-Zasada, J. (2003). The effect of calcitriol and its analogues on proliferation and hormone expres-sion in cultured cells of thyroid medullary carcinomas. Folia Mor-phol. (Warsz.) 62, 463-465.
125. Zhou, J. Y., Norman, A. W., and Chen, D. L. (1990). 1,25-Dihydroxy-16-ene-23-yne-vitamin D3 prolongs survival time of leukemic mice. Proc. Natl. Acad. Sci. U.S.A. 87, 3929-3932.
126. Zinser, G. M., and Welsh, J. (2004). Effect of Vitamin D3 receptor abla-tion on murine mammary gland development and tumorigenesis. J. Steroid Biochem. Mol. Biol. 89-90, 433-436.